Background {#Sec1}
==========

Thoracic aortic aneurysms (TAA) are a significant cause of morbidity and mortality. The actual incidence is hard to estimate as the disease usually remains silent until an acute aortic dissection (AAD) or rupture occurs. Incidence of AAD is assessed at 2--3.5/100,000 inhabitants/year in the US \[[@CR1]\]. It is also evaluated that individual lifetime risk of rupture or dissection reaches 34 % by the time aorta achieves a diameter of 6 cm \[[@CR2]\].

There are two major types of TAAs: sporadic (degenerative/atherosclerotic) and hereditary thoracic aortic aneurysms and dissections (TAAD). Familial form is found in 20--40 % of TAAD cases when at least two subjects within single family are diagnosed with TAAD \[[@CR3], [@CR4]\]. TAAD may be a part of well-characterized genetic syndromes such as Marfan syndrome (MFS), Loeys--Dietz syndrome (LDS), vascular type of Ehlers--Danlos syndrome (EDS), Shprintzen--Goldberg syndrome---all named syndromic TAAD. However most TAAD patients do not meet the criteria of those syndromes and are defined as as non-syndromic TAAD \[[@CR5]\].

After the discovery of the defect in fibrillin 1 gene (*FBN1*) as the mechanism underlying pathogenesis of MFS, and the identification of first causative mutation in 1991 \[[@CR6]--[@CR8]\], there are currently over 1300 mutations in HGMD database referred to MFS and over 3000 entries in UMD-FBN1 mutations database (<http://www.umd.be/FBN1/>). In 2003 Kroes et al. \[[@CR9]\] related EDS to mutations in *COL3A1*, the following year Mizuguchi et al. \[[@CR10]\] associated *TGFBR2* mutations with marfanoid phenotype, and finally in 2005 Loeys and colleagues distinguished and characterized LDS as the separate entity caused by defects in the *TGFBR1* and *TGFBR2* genes \[[@CR11]\]. Soon followed the discoveries of genes responsible for non-syndromic TAAD \[[@CR12], [@CR13]\]. Autosomal dominant transmission of the TAAD has been proven in vast majority of patients with the disease, although in some probands with healthy parents, de novo mutations occur.

Introduction of next-generation sequencing (NGS) enabled efficient and cost-effective examination of all coding genes (whole exome sequencing, WES) or chosen gene panels.

Aim of the study was to define the diagnostic yield of NGS in 51 TAAD patients, to search for novel mutations in TAAD-associated genes, as well as genotype-phenotype correlations within families of TAAD patients.

Methods {#Sec2}
=======

Patients and consent {#Sec3}
--------------------

The study cohort was chosen from all index patients referred with the diagnosis of TAAD for clinical genetic testing from 2012 to 2014 to the Unit for Screening Studies in Inherited Cardiovascular Diseases, Institute of Cardiology and comprised 51 unrelated patients and 64 relatives of genotype positive patients. Patients with family history of aortic disease, early onset of aortic disease, suspected connective tissue disorders were included primary. In all patients a three-to-four generation pedigree was drawn and the data on the presence of TAAD, and other diseases in the family were collected. Every effort was made to review medical data on deceased subjects to confirm familial form of TAAD. For patients suspected of MFS and their relatives revised Ghent criteria were used \[[@CR14]\] and a detailed questionnaire was applied to define the involvement of other systems and organs. Systemic score for each patient was calculated with web calculator <http://www.marfan.org/resources/professionals/marfandx>. In addition, web questionnaires were used to assess systemic features of LDS <http://www.loeysdietz.org/> and Sphrintzen--Goldberg syndrome \[[@CR15]\]. With regard to cardiovascular system, all patients had Doppler echocardiographic study and CT scan of the entire aorta. In particular, we collected the following data: age at diagnosis of all features, namely of the presence of TAA, the history of AAD, the presence of aortic arch and descending aorta dissection, the prophylactic surgery for thoracic aorta surgery (aortic root, ascending aorta). Indications for planned surgery relied on available guidelines and evolved with time. Definition of aortic root dilatation and ascending aorta dilatation were based on echocardiography with calculation of Z-score for aortic root using Web calculator <http://www.marfan.org/resources/professionals/marfandx>. According to guidelines, patients were followed-up with serial examinations by two-dimensional echocardiography and/or CT scan of the aorta. Both acute aortic dissection and first planned aortic surgery were considered aortic events. Data concerning mitral valve included presence of mitral valve prolapse (MVP) and mitral regurgitation (MR) on echocardiography. Diagnosis for MVP was based upon published criteria \[[@CR16]\]. Familial disease was defined as the presence of \>1 patient with TAAD in the family. This study was approved by the Bioethics Committee in the Institute of Cardiology (ref. no. 1273). All participants of the study gave an informed written consent including specific consent to genetic testing and permission to publish the results.

Genetic testing {#Sec4}
---------------

DNA was extracted from the peripheral blood by standard salting out method and from buccal swab using Maxwell^®^ 16 instrument with DNA IQ™ Casework Pro Kit (Promega).

In all probands sequencing was performed on HiSeq 1500. In 29 patients whole exome sequencing (WES) was performed, and in 22 TruSight One (TSO) sequencing panel (Illumina, San Diego, CA, USA) was used. WES sequencing libraries were prepared using TruSeq Exome Enrichment Kit (Illumina, San Diego, CA, USA) or Nextera Rapid Capture Exome (Illumina, San Diego, CA, USA) as described previously  \[[@CR17]\].

We considered variants located in the coding or splicing regions of one of established TAAD genes with autosomal dominant transmission pattern (Table [1](#Tab1){ref-type="table"}), of frequency no greater than 0.001 in all of three databases (1000Genomes, ESP and ExAC). Mutation was considered novel when absent from HGMD database (release 2015.1). To assess pathogenicity of novel variants we used algorithms supplied by ANNOVAR software ([http://annovar.openbioinformatics.org/en/latest/user-guide/filter/\#-lrt-annotation](http://annovar.openbioinformatics.org/en/latest/user-guide/filter/%23-lrt-annotation)). Thus identified variants were followed-up with Sanger sequencing using a 3130xL Genetic Analyzer (Applied Biosystems, Foster City, CA, USA) and BigDye Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems) according to the manufacturer's instructions. The results were analyzed with Mutation Surveyor 3.30 Software (SoftGenetics). List of primers specific to each variant is available in Additional file [1](#MOESM1){ref-type="media"}. Amplification and Sanger sequencing of the beginning of exon 1 of *SKI* because of its CG-rich content was based on modification of methods published by Naz and Fatima \[[@CR18]\]. Details are available in Additional file [1](#MOESM1){ref-type="media"}.Table 1List of analyzed genesGene*OMIM*\#*ACTA2*102620*COL3A1*120180*FBN1*134797*MYH11*160745*MYLK*600922*SKI*164780*SMAD3*603109*TGFB2*190220*TGFBR1*190181*TGFBR2*190182

Once mutation was identified, screening was offered to consenting relatives. Whenever possible we looked for co-segregation in the TAAD families.

Statistical analysis {#Sec5}
--------------------

All results for categorical variables were presented as numbers and percentages and for continuous variables as mean and standard deviation (SD). Kaplan--Meier survival curves were used to compare event-free survival between genotype positive and negative patients. All tests were two-sided with the significance level of p \< 0.05. Calculations were performed with *SPSS* package.

Results and discussion {#Sec6}
======================

Clinical findings {#Sec7}
-----------------

Table [2](#Tab2){ref-type="table"} shows summarized clinical characteristics of the study group. Mean age at the time of genetic inquest in the study group was 44 ± 13.8 years and 35 (68.6 %) patients were male. More than two-thirds of TAAD patients (n = 36, 70.6 %) had aortic events. Namely in 17 (33.3 %) patients AAD was first symptom of the disease at mean age of 40.1 years, and 19 (37.3 %) had planned aortic surgery at mean age of 44 years as first procedure. The remaining 15 (29.4 %) patients were diagnosed with TAA at mean age 39.9 years, however they did not meet criteria for surgical correction. Six patients after first operation for AAD required another surgical procedure during follow-up.Table 2Clinical characteristics of the study group, n = 51*Clinical characteristics of the study group*Age at the genetic inquest (mean ± SD, years)44.8 ± 13.8Male sex (n, %)35 (68.6)AAD (n,  %)17 (33.3)Age at AAD (mean ± SD, years)40.1 ± 13.0Planned TAA surgery (n, %)25 (49)Age at planned TAA surgery (mean ± SD, years)42.2 ± 17Planned TAA surgery---first procedure in the patient (n, %)19 (37.3)Age at the planned TAA surgery- first procedure in the patient (mean ± SD, years)44 ± 16.8TAA with no criteria for surgery (n, %)15 (29.4)Age at last examination (mean ± SD, years)39.9 ± 14.9Suspected MFS (n, %)13 (25.5)Familial TAAD25 (49)*Associated structural abnormalities (n,* *%)*BAV11 (21.6)CoA + BAV1 (1.9)ASD and LVNC1 (1.9)*Other CV diseases (n,* *%)*Stroke3 (5.8)CAD6 (11.7)Peripheral artery aneurysms3 (5.8)Hypertension33 (64.7)*Other diseases (n,* *%)*Mild-to-moderate intellectual disability2 (3.9)Rheumatid arthritis1 (1.9)

In 13 patients with TAAD genetic examination was made to confirm/exclude the diagnosis of MFS. In the whole group co-existent abnormalities included: CoA+ BAV− 1 patient, isolated BAV− 11 patients, LVNC + ASD in one patient. Peripheral artery aneurysms were present in 3 (5.8 %) patients. A history of stroke was present in 3 (5.8 %), CAD in 6 (11.7 %) patients. More than half of the all study group 33 (64.7 %) patients were hypertensive. Familial disease was found in 25 (49 %) of TAAD patients. In addition, mild to moderate intellectual disability was present in 2 patients (3.9 %), rheumatoid arthritis in 1 (1.9 %).

Mutation analysis and diagnostic sensitivity {#Sec8}
--------------------------------------------

In a total of 51 analyzed individuals we found 22 rare variants in a given panel of genes (Table [3](#Tab3){ref-type="table"}). Six (27.3 %) of these were previously reported as pathogenic in TAAD patients. Among novel variants, one was a de novo event, and two were gene-disrupting variants. Together those nine variants were classified as causative. Another nine novel missense variants were considered likely causative as segregation analysis (Figs. [1](#Fig1){ref-type="fig"}, [2](#Fig2){ref-type="fig"}) either supported their causative effect and/or pathogenicity estimations strongly suggested their damaging effect. Also, in our study we classified as likely pathogenic a variant which was previously reported as pathogenic but was detected only in *cis* configuration with another (splice site) variant. Two missense sequence changes were considered as variants of unknown significance (VUS) since there was insufficient data for segregation study and software estimations gave ambiguous results. Two variants were classified as likely benign since they showed lack of co-segregation with the disease. Overall, 9 (17.6 %) of 51 probands had a positive result when considering variants classified as causative only and 18 (35.3 %) if likely causative variants were also included. Detailed clinical characteristics of genotype positive probands and family members are shown in Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"}.Table 3Rare variants identified in our cohort and associated nomenclature, classification and database frequencyNoFamilyGeneNucleotideProteinTranscriptDomainClassificationReferencesExACESP1TAAD032*FBN1*c.6740-2A\>GSplice siteNM_000138.4cbEGF-likeCausativeThis study002TAAD001*FBN1*c.7502_7503insAN2502\*NM_000138.4cbEGF-likeCausativeThis study003TAAD012*FBN1*c.4223G\>TC1408FNM_000138.4cbEGF-likeCausativeTiecke et al. \[[@CR22]\]004TAAD080*FBN1*c.7754T\>CI2585TNM_000138.4cbEGF-likeCausativeLiu et al. \[[@CR48]\]005TAAD017*FBN1*c.5074_5076delAGAR1692delNM_000138.4--CausativeComeglio et al. \[[@CR29]\]006TAAD056*FBN1*c.7916A\>GY2639CNM_000138.4cbEGF-likeCausativeMátyás et al. \[[@CR34]\]007TAAD038*FBN1*c.2231G\>AG744ENM_000138.4cbEGF-likeLikely causativeThis study008TAAD153*FBN1*c.2950G\>AV984INM_000138.4TB5CausativeGrau et al. \[[@CR38]\]0.0000509TAAD118*TGFBR1*c.605C\>TA202 VNM_004612.2GSLikely causativeThis study0010TAAD026*TGFBR1*c.844T\>CY282HNM_004612.2Protein kinaseLikely causativeThis study0.00002011TAAD048*TGFBR2*c.1579G\>AA527TNM_003242.5Protein kinaseCausativeFrischmeyer-Guerrerio et al. \[[@CR40]\]0012TAAD146*SKI*c.59C\>AT20 KNM_003036.3R-SMAD bindingCausativeThis study0013TAAD045*SMAD3*c.868A\>TI290FNM_005902.3MH2Likely causativeThis study0014TAAD111*ACTA2*c.80A\>GD27GNM_001613.2Actin familyLikely causativeThis study0015TAAD076*ACTA2*c.350A\>GN117SNM_001613.2Actin familyLikely causativeThis study0016TAAD024*MYH11*c.5273G\>AR1758QNP_002465.1Coiled coilLlikely causativeZhu et al. \[[@CR12]\]0.00020.0002317TAAD103*MYH11*c.5499G\>CE1833DNM_002474.2Coiled coilLikely causativeThis study0.00030.0005418TAAD157*COL3A1*c.2108C\>TP703LNM_000090.3Triple-helical regionVUSThis study0019TAAD097*COL3A1*c.3869T\>CI1290TNM_000090.3NC1Likely causativeThis study0020TAAD130*MYLK*c.608C\>TP203LNM_053025.3Ig-like C2-type 2VUSThis study0021TAAD027*MYLK*c.1133G\>AR378HNM_053025.3--Likely benignThis study0.00013820.0000822TAAD048*MYLK*c.2069C\>TT690 MNM_053025.3Ig-like C2-type 5Likely benignThis study0.0000080.00008Fig. 1Pedigrees of families with fibrillinopathiesFig. 2Pedigrees of families with mutations in *ACTA2, COL3A1, TGFBR1, MYH11, SKI, SMAD3, TGFBR1* and *TGFBR2* genesTable 4Clinical and genetic characteristics of syndromic TAAD patients and related mutation carriersFamilyPosition on pedigree-statusSexAgeEctopia lentisSystemic scoreCVS-involvement of the aortaAortic rootZ-scoreIAExtensionAge at surgery^a^Type of surgery^a^CVS-otherType of syndromeGeneMutationTAAD032III:2-probandF2104TAA362.60RNAMFS*FBN1*c.6740-2A \> GTAAD032II:2-motherF5303TAA392.71RNAMFS*FBN1*c.6740-2A \> GTAAD001II:9-probandF4307AAD475.71R, As, Ar, D, Ab39SC + AMFS*FBN1*p.N2502XTAAD012II:6-probandF3212TAA507.60R32DavMFS*FBN1*p.C1408FTAAD012II:5-twin siblingF3215TAA518.10R28DavMFS*FBN1*p.C1408FTAAD080II:1-probandM480NEAADSurgery0R, As, Ar, D42AVR + SCMFS*FBN1*p.I2585TTAAD080I:1-fatherM7600AAA360.01No60ABBGMFS*FBN1*p.I2585TTAAD080II:4-sisterF4800N330.80NoNAMFS mutation carrier*FBN1*p.I2585TTAAD080II:8-sisterF3703N341.70NoNAMFS mutation carrier*FBN1*p.I2585TTAAD080III:8-nieceF1602N300.81NoNAPotential MFS*FBN1*p.I2585TTAAD080III:3-daughterF1502N332.10RNAPotential MFS*FBN1*p.I2585TTAAD017III:1-probandM4216TAA484.21R, AsNAMFS*FBN1*p.R1692delTAAD017II:1-fatherM6604N421.41RNAMFS mutation carrier*FBN1*p.R1692delTAAD056II:4-probandF6102TAA579.23R, As, Ar58BMFS*FBN1*p.Y2639CTAAD056III:3-daughterF2805TAA444.80RNAMFS*FBN1*p.Y2639CTAAD038III:2-probandM2205TAA413.20RNAMVP, MR 2+MFS*FBN1*p.G744ETAAD038II:3-fatherM4803TAA432.40RNAMVP, MR 1+MFS*FBN1*p.G744ETAAD153II:2-probandF4801TAA465.73R, As, Ar48BMFS*FBN1*p.V984ITAAD153I:3-motherF7205N351.21NoNAMFS mutation carrier*FBN1*p.V984ITAAD153IV:1-sonM2200N32−0.40NoNAMFS mutation carrier*FBN1*p.V984ITAAD153IV:2-sonM2100N29−1.20NoNAMFS mutation carrier*FBN1*p.V984ITAAD108probandM18010TAASurgery1R19BMFSNot foundNATAAD118III:7-probandM2608TAASurgery0R, As18DLDS*TGFBR1*p.A202 VTAAD048III:4-probandF4200AADSurgery1R, As, Ar, D, Ab40SCLDS*TGFBR2*p.A527TTAAD048III:1 - brotherM4304N360.70noNALDS mutation carrier*TGFBR2*p.A527TTAAD048IV:3-daughterF1907Borderline TAA362.80RNALDS*TGFBR2*p.A527TTAAD048IV:4-sonM1607Borderline TAA382.70RNALDS*TGFBR2*p.A527TTAAD146II:1-probandM26010TAA495.61RNAMVP, MR 2+SGS*SKI*p.T20 K*AAA* abdominal aortic aneurysm, *AAD* acute aortic dissection, *Ab* abdominal aorta, *ABBG* aorto--bifemoral bypass grafting, *Ar* aortic arch, *AVR* aortic valve replacement, *B* Bentall procedure, *CVS* cardiovascular system, *Dav* David procedure, *D* thoracic descending aorta, *F* female, *LDS* Loyes-Dietz syndrome, *M* male, *MR* mitral regurgitation (*0* none, *1* mild, *2* moderate, *3* severe), *MFS* Marfan syndrome, *N* normal echocardiographic study, *NA* not applicable, *NE* not examined, *R* aortic root, *SC* supracoronary ascending aortic replacement, *SC* *+* *A* supracoronary and arch prosthesis, *SGS* Shprintzen--Goldberg syndrome, *TAA* thoracic aortic aneurysm^a^Relates to primary surgical interventionTable 5Clinical and genetic characteristics of nonsyndromic mutation carriersFamilyPosition on pedigree-statusSexAgeCVS involvement of the aortaAortic RootZ-scoreExtensionAge at surgeryType of surgery^a^Cardiovascular system-otherGeneProteinTAAD026II:4-probandF52AADSurgeryR, As, Ar, D, Ab46SC*TGFBR1*p.Y282HTAAD026I:1-fatherM77TAA473.8R, As, ArNANACAD*TGFBR1*p.Y282HTAAD026III:6-sonM15N300.5NANA*TGFBR1*p.Y282HTAAD045II:1-probandM47AADSurgeryR, As, Ar, D, Ab35SC*SMAD3*p.I290FTAAD045III:2-sonM21N371.6NANA*SMAD3*p.I290FTAAD111III:5-probandM41AADSurgeryAs, Ar, D, Ab29SC*ACTA2*p.D27GTAAD111IV:1-sonM19N31−0.1NANA*ACTA2*p.D27GTAAD076III:1-probandF29AAD362.7R, Ad, Ab20SGI*ACTA2*p.N117STAAD076II:2-motherF55N300.9NANA*ACTA2*p.N117STAAD076II:3-mat uncleM57N36NENANAStroke at 39 y, MI at 42y*ACTA2*p.N117STAAD024II:3-probandF49TAASurgeryAs, Ar43SCBAV*MYH11*p.R1758QTAAD024III:1-daughterF24N300.6NANA*MYH11*p.R1758QTAAD103II:1-probandM62TAASurgeryR, As, Ar onset59Y + AVRBAV*MYH11*p.E1840DTAAD097II:1-probandM55AADSurgeryAs, Ar, D, Ab40SC + A*COL3A1*p.I1290TTAAD097II:5-sisterF50TAA443.4R, As*COL3A1*p.I1290TTAAD097III:1-sonM33Borderline TAA422.0R*COL3A1*p.I1290TTAAD097III:4-daughterF28N321.1*COL3A1*p.I1290T*AAD* acute aortic dissection, *Ab* abdominal aorta, *Ar* aortic arch, *As* ascending aorta, *AVR* aortic valve replacement, *BAV* bicuspid aortic valve, *CAD* coronary artery disease, *CVS* cardiovascular system, *D* thoracic descending aorta, *F* female, *HT* arterial hypertension, *M* male, *MI* myocardial infarction, *N* normal echocardiographic study, *NA* not applicable, *NE* not examined, *R* aortic root, *SC* supracoronary ascending aortic replacement, *SC* *+* *A* supracoronary and arch prosthesis, *SGI* stent graft implantation, *TAA* thoracic aortic aneurysm, *Y* Yacoub procedure^a^Relates to primary surgical intervention

There were 3 recently published studies which applied NGS for molecular diagnosis of both syndromic and non-syndromic TAAD. Wooderchak-Donahue et al. used a panel of 10 genes in the group of 175 patients. Overall they found 51 rare variants, 10 % of patients had variants classified as pathogenic and 18 % had VUS (CNV's found by SGH-array not included) \[[@CR19]\]. Proost et al. used panel of 14 genes to study 55 individuals and reported 15 causative variants and 6 VUS achieving 27 % clinical sensitivity \[[@CR20]\]. Ziganshin et al. \[[@CR21]\] used WES to study 102 patients, of whom 72.5 % had no potentially relevant alterations in 21 genes analyzed. Only 4 % of participants had variants which authors considered as deleterious and 22 % had previously unreported VUS. In comparison with the above mentioned studies the diagnostic yield in our study (i.e. 35.3 %) was relatively high which may be possibly caused by a relatively severe disease in our cohort (see below the section on genotype phenotype correlations and the data indicating that causative mutations are more often detected in severe disease). The generally low diagnostic yield (≪50 %) observed in all the studies indicates that in the major proportion of patients the disease is caused by factors (genetic or environmental) which are at present unknown.

Genotype phenotype correlations {#Sec9}
-------------------------------

Kaplan--Meier survival curve was constructed to compare the event-free survival between probands defined as 'genotype-positive' (i.e. those with causative/likely causative variants) and 'genotype-negative' reference group (i.e. those without any plausible variant identified, including VUS and likely benign variants). Aortic events were defined as acute aortic dissection or first planned aortic surgery. Genotype-positive probands showed shorter mean event free survival (41 years, CI 35--46) than those who were genotype-negative (51 years, CI 45--57, p = 0.0083, Fig. [3](#Fig3){ref-type="fig"}). Interestingly, this effect was also found when the 'genotype-positive' group was restricted to probands with variants classified as 'likely causative': 37 years (CI 28--47) vs. 51 years (CI 45--57, p = 0092, Additional file [1](#MOESM1){ref-type="media"}: Figure S1). This latter observation argues that majority (if not all) of the variants classified as 'likely pathogenic' are functionally relevant. The generally faster disease progression among subjects with causative/likely causative variants suggests that the currently known TAAD loci are those associated with the most severe disease.Fig. 3Kaplan--Meier analysis of event free survival in TAAD in probands with variants classified as causative/likely causative vs. those without any candidate variants identified (Log-Rank Chi- square 6.97, p = 0.0083)

When we considered functional pathway altered by mutation, we found that the mean event free survival was 37 years (CI 27--47, p = 0.0033 vs. the 'genotype-negative' reference group, Additional file [1](#MOESM1){ref-type="media"}: Figure S2) among the probands with defects in the TGF beta signaling (i.e. those with *TGFBR1*, *TGFBR2*, *SMAD3* or *SKI* mutations). The mean event free survival for probands with *FBN1* mutations was 45 years (CI 36--53, NS vs. the reference), whereas for the remaining probands with causative/likely causative variants (i.e. those with mutations in *ACTA2, MYH11* or *COL3A1*) it was 38 years (CI 24--52, NS vs. the reference). The particularly fast disease progression associated with defects in TGF beta signaling has been observed previously \[[@CR5]\].

Pedigrees of families with mutations in *FBN1* are shown in Fig. [1](#Fig1){ref-type="fig"} and those with the remaining mutations in Fig. [2](#Fig2){ref-type="fig"}. Detailed clinical characteristics of genotype positive probands and their family members are presented in Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"}.

FBN1 {#Sec10}
----

Similar to previous reports \[[@CR19], [@CR20]\] *FBN1* variants were the most abundant in our study group. Among eight *FBN1* mutations identified, 3 were novel: c.6740-2A\>G disrupting splice site acceptor, c.7502_7503insA (p.N2502\*) introducing stop codon at exon 61, and p.G744E affecting calcium binding epidermal growth factor-like domain (cb EGF-like).

The proband carrying *FBN1* c.6740-2A\>G (family TAAD032) is a 21-year-old woman who was suspected of MFS because of TAA with Z-score of 2.6 and mild systemic features with systemic score of four points. The proband's mother was 53-year-old woman, with positive family history of AAD (her sister died at age of 31 in 6th month of pregnancy, and her mother died suddenly at age of 27 years). She had TAA with Z-score 2.7, systemic score of 3 points, no ocular involvement. In summary, without genetic examination the diagnosis of MFS would not be possible in the family.

p.N2502\* was found in a 43-year-old patient (family TAAD001), suffering from AAD (Stanford, type A) at age of 39 years, without diagnosis of MFS, without remarkable family history. Based on clinical features, she met systemic criteria (seven points) for the diagnosis of MFS. Family history was negative. MFS could be diagnosed on the basis of TAAD and systemic score, identification of *FBN1* truncating variant confirmed the clinical diagnosis.

*FBN1* p.G744E variant was identified in 22-year-old proband and his 48-year-old father with suspected MFS (family TAAD038). None of them had ectopia lentis or met systemic criteria for the diagnosis of MFS. The proband had surgical correction of pectus excavatum at age of 14 years, and had significant myopia (−9D). His major problem was prolapse of both leaflets of the mitral valve with significant mitral insufficiency, enlarged left ventricle (LVEDD 62 mm) with preserved left ventricular systolic function (LVEF 64 %). In addition dilated aortic root (Z-score 3.2) was present at age of 22 years. His father with myopia of −3D also had mitral valve prolapse, however with mild mitral insufficiency and dilated aortic root with Z-score of 2.4. The disease is more aggressive in the proband than in his father.

Four of previously reported *FBN1* mutations (p.C1408F, p.I2585T, p.R1692del, and p.Y2639C) were located in cb EGF-like domains, and one (p.V984I) in TGFβ Binding-Protein-Like Domain 5 (TB5).

p.C1408F has been once reported previously \[[@CR22]\], however, there are two more reports of another alteration in the same cysteine residue in MFS patients \[[@CR23], [@CR24]\] indicating that the position may be a mutational hot spot. p.C1408F was found in monozygotic affected female twins from our study group (family TAAD012). Both twins had ectopia lentis, and required prophylactic aortic surgery due to TAA at age of 28 and 32 years. The variant is probably de novo in the family as two sisters were free of mutation and parents were without any remarkable history.

*FBN1* p.I2585T first reported by Liu et al. is one of the most recurrent MFS-causing mutations. According to the UMD-FBN1 mutations database this variant was detected in 30 MFS patients of either Asian or Caucasian descent \[[@CR24]--[@CR31]\]. We found a remarkable clinical variability in the family with six mutation carriers in three generations (family TAAD080). Involvement of the cardiovascular system was present in the proband (AAD of the thoracic aorta at age of 42 years, rapidly progressive after emergency surgery) and in the proband's father (no TAA, however aneurysm of the abdominal aorta was present corrected surgically at age of 60 years). Two proband's sisters had only skeletal involvement with scoliosis, in two mutation carriers of the youngest generation we diagnosed potential MFS.

There are two reports of MFS patients with *FBN1* p.R1692del mutation. The first concerns a patient after vascular and/or valve surgery \[[@CR32]\] and the second a 7 years old child with ectopia lentis and minor skeletal and no cardiovascular involvement \[[@CR29]\]. Larger in frame deletion in the same exon (5074_5097del) was reported in Weill-Merchesani syndrome \[[@CR33]\]. In our family with two mutation carriers (family TAAD017), only proband 42-year-old met criteria for classic MFS with both ectopia lentis and TAA. His father did not have either ocular involvement or TAA but as he is a mutation carrier, he can be diagnosed as MFS genetically predisposed.

*FBN1* p.Y2639C was first reported by Matyas et al. \[[@CR34]\], since then it has been found in several other studies on MFS and related disorders \[[@CR25], [@CR35], [@CR36]\] including a report describing 19 individuals carrying p.Y2639C in a single family who showed extensive clinical variability from minor skeletal abnormalities to full diagnostic criteria for MFS with TAAD and mitral valve prolapse \[[@CR37]\]. In our family (TAAD056) the proband was 61 years old female diagnosed at age of 58 years because of a history of exertional dyspnea, severe aortic insufficiency with aortic root dilatation of 57 mm and generalized hypokinesis of the left ventricle with LVEF of 46 %. She underwent Bentall procedure which led to restoration of left ventricular function. Her daughter had TAA diagnosed at the age of 28 years with Z-score of 4.8. None of them had ectopia lentis or reached systemic score of seven points, therefore MFS could only be diagnosed based on genetic examination and the presence of TAA.

*FBN1* p.V984I is located in so-called neonatal region of *FBN1* where all reported mutations associated with neonatal MFS and the majority of point mutations associated with atypically severe presentations were found \[[@CR22]\] although it has been previously found also in a male patient with classical MFS \[[@CR38]\]. Our 48-year-old female proband (TAAD153) has a history of Bentall procedure due to severe aortic insufficiency and dilatation of the aortic root and ascending aorta. Interestingly, the proband had also tortuosity of the vessels and impaired healing of wounds. The diagnosis of MFS in the proband was possible only after genetic examination. Among the remaining three mutation carriers (proband's mother and proband's sons) none had TAA. Proband's mother had minor skeletal involvement.

TGFBR1 and TGFBR2 {#Sec11}
-----------------

We found three rare variants in genes coding TGFβ receptors, all located within serine threonine kinase domain of both proteins where the most of pathogenic missense variants are being found \[[@CR39]\]. p.A527T in *TGFBR2* has been reported previously in LDS patient \[[@CR40]\]. Two novel variants in *TGFBR1* (p.A202V and p.Y282H) we assumed to be likely causative.

*TGFBR1* p.A202V was identified in 26 years old male with MFS diagnosed on the basis of systemic criteria and the presence of TAA (family TAAD118). His father died of AAD at age of 40 years. There was no ocular involvement. The patient underwent David's procedure at age of 18 years. In addition dilation of the proximal parts of both coronary arteries, the brachiocephalic trunk, and the pulmonary artery were found. At age of 6 years he was operated on because of horseshoe kidney.

*TGFBR1* p.Y282H was identified in 52 years old female hypertensive patient (family TAAD026), who suffered from AAD type A at the age of 46 years, with chronic dissection of thoraco-abdominal aorta, without systemic features characteristic of MFS, with hyperopia (+7D). The variant came to her from her 77 years old father with TAA (aortic root 47 mm, Z-score 3.8), with coronary heart disease (post inferior MI), treated with CABG at the age of 67 years, and PCI at the age of 69 years. Her son is asymptomatic mutation carrier.

The proband carrying p.A527T in the *TGFBR2* gene is a 42-year-old woman (family TAAD048) with a history of type A AAD at the age of 40 and rapid progression following emergency operation (the implantation of an ascending aortic prosthesis in supracoronary position) requiring additional two-step procedures: (Bentall operation with the aortic arch replacement and descending thoracic aorta replacement 9 months later). The patient presents few features of LDS type 1 such as hypertelorism and cervical spine instability, no bifid uvula and no typical signs of MFS. At the age of 17 she underwent surgery for branchial cleft cyst, later she required repetitive surgery for recurrent umbilical hernia, lower limb varicose veins and hemorrhoids. She also suffers from allergic disease which is consistent with recently published study pointing to the strong predisposition to allergies among LDS patients due to altered TGFβ signaling \[[@CR40]\]. MRI of the whole arterial tree revealed arterial tortuosity of the intracranial arteries. On repetitive CT thoraco-abdominal scans an aneurysm of the hepatic artery was also identified. The proband's mother died at the age of 67 subsequently to type B aortic dissection. Both proband's children tested positive for *TGFBR2* gene mutation. In the second decade of life they met systemic criteria for the diagnosis of MFS and had aortic root dilatation with Z-score 2.7 and 2.8, respectively. The proband's brother, another mutation carrier, at age of 43 years had no aortic root dilation and mild involvement of other tissues features. At age of 41 he experienced spontaneous pneumothorax.

SKI {#Sec12}
---

De novo *SKI* p.T20K mutation has been found in a proband with clinical suspicion of Shprintzen--Goldberg syndrome (family TAAD146). So far, all discovered variants causing this syndrome occurred in exon 1, between amino acid residues 21 and 117. Mutations in this area (some of them recurrent) cluster between two regions: one encoding R-SMAD binding domain and the other encoding start of Dachshund-homology domain (DHD) \[[@CR41]\]. This is the first report of SGS-causing variant affecting residue 20 which also is a part of R-SMAD binding domain emphasizing the role of this region of the gene in disease pathogenesis.

The 26 years old proband had TAA (aortic root size diameter 48.5 mm, Z-score 5.6), dilated pulmonary artery (31 mm), mesotelesystolic prolapse of both mitral leaflets with moderate mitral insufficiency, mitral ring of 51.4 mm, dilated left ventricle of 66 mm (LVEDD), dilated left atrium of 43 cm^2^ and LVEF of 55 % (Fig. [4](#Fig4){ref-type="fig"}). Systemic score for MFS was nine. Other abnormalities included the following: craniofacial findings (dolichocephaly, downslanting palpebral features, malar flattening, high narrow palate with prominent palatine ridges and retrognathia) and skeletal findings (dolichostenomelia, arachnodactyly, pectus carinatum, scoliosis, pes planus, foot and knee malposition). Of importance, joint hypermobility made it difficult for the patient to keep balance on the moving bus. Of the neurological anomalies moderate intellectual disability was found with the patient not able to perform any work. Other abnormalities included myopia (−4/−4.5D) along with astigmatism. In addition, the patient suffered from recurrent hypertrophy of the third tonsil that restricted his breathing, operated on four times.Fig. 4Cardiovascular imaging study in the patient with *SKI* p.T20 K variant. **a** 2D transthoracic echocardiography of parasternal long axis demonstrated aortic root aneurysm with Valsalva sinuses diameter of 48.5 mm.; **b** and **d** 2D transthoracic echocardiography in apical four chamber view in diastole. Enlarged left ventricle and left atrium with increased mitral annular diameter of 51.4 mm; **c** contrast-enhanced, ECG-gated CT, volume rendering (VR) image, the aneurysm of the ascending aorta; **d** *color flow* Doppler study revealed significant mitral regurgitation due to thickened and floppy mitral valve leaflets and widened mitral annulus

SMAD3 {#Sec13}
-----

*SMAD3* p.I290F, identified in a male proband (family TAAD045) with AAD at the age of 47 years is a novel variant located in Mad homology 2 (MH2) domain highly conserved among different species and other SMAD proteins. Neighboring variants from this locus have been repeatedly reported in aneurysm-osteoarthritis syndrome \[[@CR42], [@CR43]\]. The proband who had a history of hypertension and suffered from AAD type A at the age of 35 years, died of complications of dissected abdominal aorta at the age of 47 years. The family history was positive for heart disease (mother died at the age of 46 years, and brother died at the age of 26 years because of aortic aneurysm). One of his sons, the mutation carrier, at the age of 21 years presented with hypertension and mildly dilated aortic root with Z-score 1.6. None of the mutation carriers had any history of osteoarthritis. However, elder of his sons, aged 23 years, free of the mutation and dilation of the aorta despite hypertension was operated on because of extraarticular, tenosynovial chondromatosis at age of 9 years. Furthermore his daughter, genetically not tested, at age of 18 years with normal aortic dimensions, also had tenosynovial chondromatosis.

MYH11 {#Sec14}
-----

The proband carrying *MYH11* p.E1840D (family TAAD103) was 62-year-old patient with BAV, TAA and a history of hypertension well controlled on two drugs, after planned procedure of aortic mechanical valve implantation SJM 25 mm plus supracoronary graft at age of 59 years, with a history of rheumatoid arthritis. No PDA on angio CT scan of the aorta. The patient's daughter, aged 32 years was free of aortic disease and the mutation-free.

The 49-year-old proband carrying *MYH11* p.R1758Q (family TAAD1758) was diagnosed with BAV and TAA. At the age of 44 she underwent the supracoronary aortic graft implantation. At the age of 49 she was found to have nonprogressive aortic arch dilatation (42 mm). One of her two daughters is the asymptomatic carrier of the mutation.

Two *MYH11* mutations, identified in our probands: p.E1840D---a novel mutation and a previously reported p.R1758Q \[[@CR12]\] are both localized in myosine tail. However, according to the previous report the p.R1758Q was identified only in the presence of another variant which resulted in skipping of exon 32 \[[@CR12]\]. The deletion segregated with disease in studied family and was predicted to affect myosine tail domain's coiled-coil structure and the assembly of myosin thick filaments. It was not clear whether the additional presence of p.R1758Q in some affected individuals had any effect \[[@CR12]\]. Although *MYH11* mutations are described to cause TAA and PDA, families with incomplete segregation have been reported suggesting existence of other yet unknown genetic factors contributing to observed phenotypes. Thus, authors emphasize the need for caution during genetic counseling for families with *MYH11* mutations and patients not carrying family-specific *MYH11* variant should not be excluded from further surveillance \[[@CR44]\]. This might also be the case in the family TAAD103 in which p.E1840D proband's granddaughter was diagnosed with PDA while her mother was negatively tested for p.E1840D. However in many cases there is not enough data to determine if *MYH11* variants (including p.E1840D and p.R1758Q) are sufficient to cause TAA or should be classified as VUS. However, considering common clinical traits (in our unrelated patients we found lack of PDA and the presence of bicuspid aortic valve, Figs. [5](#Fig5){ref-type="fig"}, [6](#Fig6){ref-type="fig"}) and relative proximity of both variants within coiled coil domain, we decided to classify them as likely pathogenic.Fig. 5Cardiovascular imaging study in the patient with *MYH11* p.E1840D variant. **a** contrast-enhanced, ECG-gated CT, multiplanar reformatted image with reconstruction parallel to aortic valve shows bicuspid aortic valve in diastole; **b** volume rendering (VR) image, the aneurysm of the thoracic aorta: root of 43 mm, ascending aorta- of 52 mm (maximum dimension) and aorta before the origin of brachiocephalic trunk of 40 mm, farther arch dimension is normal of 28 mmFig. 6Cardiovascular imaging study in the patient with *MYH11* p.R1758Q variant. **a** contrast-enhanced, ECG-gate CT, multiplanar reformatted images with reconstruction parallel to aortic valve show bicuspid aortic valve in diastole; **b** volume rendering (VR) image shows supracoronary prosthesis and dilated aortic arch. Variant anatomy: common origin of brachiocephalic and left common carotid artery. Aortic arch diameter before the anomaly of 42 mm

ACTA2 {#Sec15}
-----

Both *ACTA2* mutations detected in our cohort (p.D27G and p.N117S) are novel, although another change at residue 117 as well as adjacent 118 have been reported in families with *ACTA2* associated vascular diseases including TAAD and premature CAD or stroke \[[@CR45]\].

*ACTA2* p.D27G was found in a 41 years old patient (family TAAD111), hypertensive, following AAD at the age of 29 years, operated with insertion of supracoronary aortic prosthesis 29 mm, with chronic dissection of thoraco-abdominal aorta and positive family history for aggressive TAAD. Both his father and father's sister suffered from AAD and died during the corrective surgery at the age of 44 and 52 years, respectively. Their mother had planned surgery because of TAA at the age of 70 years. The patient did not exhibit any features of any other tissue involvement, no iris flocculi. His son is a 19 years old asymptomatic mutation carrier.

*ACTA2* p.N117S was detected in a 29-year-old female (family TAAD076) who suffered type B AAD at the age of 18 while playing tennis. Within a decade she required three farther corrective procedures on her thoraco-abdominal aorta. She does not present any other tissue involvement. At the age of 29 years she had also TAA with Z-score 2.7. The proband's mother is an asymptomatic mutation carrier. She was diagnosed for mild arterial hypertension and hypercholesterolemia, but transthoracic echocardiography revealed normal aortic dimensions. No iris flocculi were found in the mutation carriers. The proband's uncle, also mutation carrier had premature ischemic stroke at the age of 39 years and premature myocardial infarction at the age of 42. During the following years, he required repeated percutaneous coronary interventions and finally, at the age of 50 he underwent coronary artery by-pass grafting. On available medical records his aorta was within normal range.

COL3A1 {#Sec16}
------

Over 95 % of pathogenic missense variants in *COL3A1* are substitutions of glycine--amino acid essential for the assembly of collagen triple helix. Remaining missense variants are reported as benign or VUS. Same applies to p.P703L which in absence of any pedigree-derived evidence indicating its pathogenicity must be classified as VUS. p.I1290T however is located in noncollagenous C-terminal globular (NC1) domain responsible for both fibril formation and cross-linking between collagen molecules in the extracellular matrix \[[@CR46]\]. At least one other variant in this region has been reported in EDS type IV \[[@CR47]\]. Combining this data with segregation analysis and software predictions, we classified this variant as likely pathogenic. p.I1290T was found in a 55 years old proband (family TAAD097), who suffered from Stanford type A AAD at age of 40 years, and was re-operated at the age of 51 because of progressive aortic root dilatation with severe aortic insufficiency along with coronary artery bypass grafting (LIMA-LAD) due to CAD. His sister was diagnosed with TAA (aortic root Z-score 3.4), and his son at age of 33 years met borderline criteria for the diagnosis of TAA. The proband's daughter is the mutation carrier with normal aortic dimensions.

MYLK {#Sec17}
----

Two (p.R378H and p.T690M) out of three rare missense variants we have found in the *MYLK* gene showed no segregation with the disease and we observed no modifying effect on patients' phenotypes so we classified them as likely benign. The third *MYLK* variant (p.P203L) was considered as VUS after considering both ambiguous results given by pathogenicity estimating software and lack of definite segregation.

Conclusions {#Sec18}
===========

This study broadens the spectrum of genetic background of thoracic aneurysms and dissections and supports its potential role as a prognostic factor in the patients with the disease.
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